Pieter Van Vlierberghe Selected Research

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL)

12/2022	Multiomics to investigate the mechanisms contributing to repression of PTPRC and SOCS2 in pediatric T-ALL: Focus on miR-363-3p and promoter methylation.
1/2021	MYB rearrangements and over-expression in T-cell acute lymphoblastic leukemia.
1/2021	Cross-talk between GLI transcription factors and FOXC1 promotes T-cell acute lymphoblastic leukemia dissemination.
1/2021	T-ALL can evolve to oncogene independence.
1/2021	RUNX2 regulates leukemic cell metabolism and chemotaxis in high-risk T cell acute lymphoblastic leukemia.
1/2021	A Tumor Suppressor Enhancer of PTEN in T-cell development and leukemia.
12/2020	Large-scale circular RNA deregulation in T-ALL: unlocking unique ectopic expression of molecular subtypes.
11/2020	Aging of preleukemic thymocytes drives CpG island hypermethylation in T-cell acute lymphoblastic leukemia.
1/2020	Three-dimensional chromatin landscapes in T cell acute lymphoblastic leukemia.
1/2020	Posttranslational Regulation of the Exon Skipping Machinery Controls Aberrant Splicing in Leukemia.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Pieter Van Vlierberghe Research Topics

Disease

35	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 12/2022 - 04/2008
26	Neoplasms (Cancer) 12/2022 - 04/2010
26	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 02/2022 - 11/2010
22	Leukemia 01/2022 - 04/2010
3	Lymphoma (Lymphomas) 10/2021 - 12/2009
3	Juvenile Myelomonocytic Leukemia 01/2021 - 11/2018
3	T-Cell Leukemia (Leukemia, T Cell) 01/2020 - 11/2010
3	Hematologic Neoplasms (Hematological Malignancy) 01/2020 - 08/2014
2	Multiple Myeloma 11/2021 - 03/2021
2	B-Cell Lymphoma (Lymphoma, B Cell) 01/2021 - 12/2014
1	Cholangiocarcinoma 05/2022
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 05/2022
1	Colonic Neoplasms (Colon Cancer) 05/2022
1	Glioblastoma (Glioblastoma Multiforme) 05/2022
1	Genomic Instability 01/2022
1	Oncogene Addiction 01/2021
1	Chromosome Aberrations (Chromosome Abnormalities) 01/2021
1	Dysbiosis 01/2020
1	Melanoma (Melanoma, Malignant) 01/2020
1	Residual Neoplasm 01/2020
1	Chromosome Breakage 01/2019
1	monosomy Chromosome 7 03/2016

Drug/Important Bio-Agent (IBA)

12	Transcription Factors (Transcription Factor)IBA 01/2021 - 04/2010
11	Proteins (Proteins, Gene)FDA Link 01/2021 - 04/2008
9	MicroRNAs (MicroRNA)IBA 12/2022 - 12/2009
5	ChromatinIBA 01/2022 - 08/2014
5	RNA (Ribonucleic Acid)IBA 12/2020 - 12/2014
5	Long Noncoding RNAIBA 11/2018 - 12/2014
4	DNA (Deoxyribonucleic Acid)IBA 11/2020 - 05/2010
3	Pharmaceutical PreparationsIBA 02/2022 - 07/2017
3	Asparaginase (Elspar)FDA Link 02/2022 - 01/2018
3	CytokinesIBA 01/2022 - 01/2020
3	Histones (Histone)IBA 01/2022 - 10/2014
3	GlucocorticoidsIBA 11/2021 - 01/2020
3	Polycomb Repressive Complex 2IBA 12/2018 - 02/2012
2	Lysine (L-Lysine)FDA Link 01/2022 - 10/2014
2	withaferin AIBA 11/2021 - 03/2021
2	Phosphotransferases (Kinase)IBA 11/2021 - 01/2020
2	Peptides (Polypeptides)IBA 01/2021 - 12/2020
2	lens epithelium-derived growth factorIBA 01/2021 - 01/2018
2	Circular RNAIBA 12/2020 - 01/2020
2	SteroidsIBA 11/2019 - 12/2016
2	Protein Isoforms (Isoforms)IBA 01/2019 - 11/2017
2	EnzymesIBA 01/2019 - 01/2018
2	Biological ProductsIBA 03/2016 - 08/2015
1	Telmisartan (Micardis)FDA Link 05/2022
1	Itraconazole (Sporanox)FDA LinkGeneric 05/2022
1	Dapsone FDA Link 05/2022
1	Disulfiram (Antabuse)FDA Link 05/2022
1	Celecoxib (Celebrex)FDA Link 05/2022
1	Pyrimethamine (Daraprim)FDA Link 05/2022
1	Drug CombinationsIBA 02/2022
1	AsparagineIBA 02/2022
1	Essential Amino AcidsIBA 02/2022
1	HeterochromatinIBA 01/2022
1	InterferonsIBA 01/2022
1	Satellite DNA (Satellite DNAs)IBA 01/2022
1	StaurosporineIBA 11/2021
1	Protein Kinase InhibitorsIBA 11/2021
1	Cyclin D2IBA 10/2021
1	Peptide Hydrolases (Proteases)FDA Link 10/2021
1	CyclinsIBA 10/2021
1	Cysteine (L-Cysteine)FDA Link 03/2021
1	Agammaglobulinaemia Tyrosine KinaseIBA 03/2021
1	Myeloid Cell Leukemia Sequence 1 ProteinIBA 01/2021
1	T-Cell Acute Lymphocytic Leukemia Protein 1IBA 01/2021
1	Tetracycline (Achromycin)FDA LinkGeneric 01/2021
1	AlbuminsIBA 01/2021
1	GANT 61IBA 01/2021
1	Decitabine FDA Link 11/2020
1	H3B-8800IBA 01/2020
1	RNA Splicing FactorsIBA 01/2020
1	Zinc Finger E-box Binding Homeobox 2IBA 01/2020
1	Ubiquitin-Specific Peptidase 7IBA 01/2020
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2020
1	Arginine (L-Arginine)FDA Link 01/2020
1	Serine (L-Serine)FDA Link 01/2020
1	Interleukin-7 (Interleukin 7)IBA 01/2020
1	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2020
1	Proteasome InhibitorsIBA 01/2020
1	Ubiquitin-Specific ProteasesIBA 01/2019
1	LuciferasesIBA 01/2019
1	Histone DemethylasesIBA 01/2019
1	Deubiquitinating EnzymesIBA 01/2019
1	Small Nuclear RNA (snRNA)IBA 10/2018
1	Small Nucleolar RibonucleoproteinsIBA 10/2018
1	AZD5153IBA 10/2018
1	GlutaminaseIBA 01/2018
1	Messenger RNA (mRNA)IBA 11/2017
1	Biomarkers (Surrogate Marker)IBA 07/2017
1	Fetal Hemoglobin (Hemoglobin F)IBA 03/2016
1	venetoclaxIBA 12/2014
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 04/2011

Therapy/Procedure

13	Therapeutics 02/2022 - 04/2011
7	Drug Therapy (Chemotherapy) 01/2020 - 12/2014
3	Hematopoietic Stem Cell Transplantation 01/2021 - 01/2015
1	Induction Chemotherapy 01/2020
1	Cranial Irradiation 01/2019
1	Ligation 01/2017
1	Salvage Therapy 08/2015